

USFHP Prior Authorization Request Form for
apremilast (**Otezla**)

To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) US Family Health Plan Pharmacy Program. US Family Health Plan is a TRICARE contractor for DoD.

The completed form may be faxed to 855-273-5735

OR

The patient may attach the completed form to the prescription and **mail** it to:

Attn: Pharmacy, 77 Warren St, Brighton, MA 02135

QUESTIONS? Call 1-877-880-7007

<https://www.usfamilyhealth.org/for-providers/pharmacy-information/>

Prior authorization does not expire. Clinical documentation may be required.

Step 1 Please complete patient and physician information (please print):

1

Patient Name: _____
Address: _____

Sponsor ID # _____
Date of Birth: _____

Physician Name: _____
Address: _____

Phone #: _____
Secure Fax #: _____

Step 2 Please complete clinical assessment:

2

1. How old is the patient?	☐ Less than 6 years of age- STOP - Coverage not approved ☐ 6 to 17 years of age – proceed to question 3 ☐ 18 years of age or older - proceed to question 2	
2. What is the indication or diagnosis for adult patients (18 years of age or older)?	☐ Active psoriatic arthritis – proceed to question 7 ☐ Moderate to severe plaque psoriasis in a patient who is a candidate for phototherapy or systemic therapy – proceed to question 7 ☐ Mild plaque psoriasis in a patient who is a candidate for systemic therapy or phototherapy– proceed to question 5 ☐ Oral ulcers associated with Behcet's disease – proceed to question 12 ☐ Other indication or diagnosis – STOP: Coverage not approved.	
3. What is the indication or diagnosis for pediatric patients (6 to 17 years of age)?	☐ Moderate to severe plaque psoriasis in a patient who is a candidate for systemic therapy or phototherapy - proceed to question 4 ☐ Moderate to severe psoriatic arthritis - proceed to question 4 ☐ Other indication or diagnosis – STOP: Coverage not approved.	
4. Does the patient weigh AT LEAST 20 kg?	☐ Yes proceed to question 7	☐ No STOP Coverage not approved

USFHP Prior Authorization Request Form for
apremilast (**Otezla**)

5. Does the patient have a contraindication to, intolerability to, or has failed treatment with medications from at least TWO of these THREE categories: • Moderate to High Potency Topical Corticosteroids (class 1 - class 5) for example, clobetasol propionate 0.05% ointment/cream, fluocinonide 0.05% ointment/cream, betamethasone dipropionate 0.05% cream/lotion/ointment, etc.; • Steroid Sparing Agents: Vitamin D analogs (for example, calcipotriene and calcitriol), tazarotene, or topical calcineurin inhibitors (for example, tacrolimus and pimecrolimus); • Other Topicals: emollients, salicylic acid, anthralin, or coal tar?	☐ Yes proceed to question 6	☐ No STOP Coverage not approved
6. Does the patient have a contraindication to, intolerability to, inability to access treatment, or has failed treatment with phototherapy?	☐ Yes proceed to question 11	☐ No STOP Coverage not approved
7. Humira is the Department of Defense's preferred targeted biologic agent. Has the patient tried Humira?	☐ Yes proceed to question 8	☐ No proceed to question 10
8. Has the patient had an inadequate response to Humira?	☐ Yes proceed to question 11	☐ No proceed to question 9
9. Has the patient experienced an adverse reaction to Humira that is not expected to occur with the requested agent?	☐ Yes proceed to question 11	☐ No STOP Coverage not approved
10. Does the patient have a contraindication to Humira?	☐ Yes proceed to question 11	☐ No STOP Coverage not approved
11. Has the patient had an inadequate response to non-biologic systemic therapy? (For example: methotrexate, aminosaliclates [for example, sulfasalazine, mesalamine], corticosteroids, immunosuppressants [for example, azathioprine], etc.)	☐ Yes proceed to question 12	☐ No STOP Coverage not approved

12. Will the patient be receiving other targeted immunomodulatory biologics with Otezla, including but not limited to the following: Actemra, Cimzia, Cosentyx, Enbrel, Humira, Ilumya, Kevzara, Kineret, Olumiant, Orenicia, Remicade, Rituxan, Siliq, Simponi, Stelara, Taltz, Tremfya, Xeljanz/Xeljanz XR, Skyrizi, or Rinvoq ER?	☐ Yes proceed to question 13	☐ No Sign and date below
13. Please explain referencing literature to support combination use with Otezla and attests that the patient will be monitored closely for adverse effects.	_____ Sign and date below	

3

Date _____